Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain NBIX message board posts where the ticker symbol NBIX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest NBIX SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 5.02
Acc-no: 0001193125-18-281188 (34 Act)  Size: 16 KB
2018-09-24 000-22705
181083579
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-049721 Size: 18 KB
2018-09-05
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001193125-18-254973 (33 Act)  Size: 75 KB
2018-08-22 333-226971
181032364
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-045265 Size: 8 KB
2018-08-03
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-045264 Size: 8 KB
2018-08-03
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001193125-18-238227 (34 Act)  Size: 220 KB
2018-08-03 000-22705
18991773
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-18-018151 (34 Act)  Size: 6 MB
2018-07-31 000-22705
18982072
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-18-018134 (34 Act)  Size: 262 KB
2018-07-31 000-22705
18981620
8-K  Documents Current report, item 8.01
Acc-no: 0001193125-18-224539 (34 Act)  Size: 16 KB
2018-07-24 000-22705
18966345
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-040121 Size: 22 KB
2018-06-29
More NBIX SEC Filings


Related news from
Wed, 17 Oct 2018
13:40:09 +0000
How Acadia Pharmaceuticals Is Positioned Financially
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.
Mon, 15 Oct 2018
20:01:00 +0000
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, Nov. 5, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participants can access the live conference call by dialing 877-876-9176 (US) or 785-424-1667 (International) using the conference ID: NBIX.
Mon, 15 Oct 2018
12:35:00 +0000
New Research: Key Drivers of Growth for Neurocrine Biosciences, SS&C Technologies, Quaker Chemical, Sealed Air, KLA-Tencor, and Summit Hotel Properties — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Mon, 15 Oct 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Tesaro and Neurocrine Biosciences
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...
Thu, 11 Oct 2018
12:13:54 +0000
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Wed, 10 Oct 2018
20:54:08 +0000
Neurocrine Inks Deal with Private Biotech to Make CNS Drugs
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
Tue, 09 Oct 2018
20:01:00 +0000
Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders
SAN DIEGO and BOSTON, Oct. 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders. The collaboration will leverage Jnana's proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine's research and development expertise in CNS disorders to advance new medicines.
Tue, 09 Oct 2018
14:30:53 +0000
A Financial Overview of Neurocrine Biosciences in October
Neurocrine Biosciences’ (NBIX) revenues grew from $6.3 million in the second quarter of 2017 to $96.9 million in the second quarter. The company reported net revenues of $168.0 million in the first half of this year, which grew from $6.3 million in the first half of 2017. Wall Street analysts expect Neurocrine Biosciences to generate revenues of $151.8 million in the third quarter.
Tue, 09 Oct 2018
11:32:17 +0000
Analysts Are Mostly Positive on Neurocrine Biosciences
Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.
Mon, 08 Oct 2018
15:51:03 +0000
AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis
AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.
Fri, 05 Oct 2018
21:13:00 +0000
AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis
AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis
Fri, 05 Oct 2018
13:30:01 +0000
UTHR vs. NBIX: Which Stock Is the Better Value Option?
UTHR vs. NBIX: Which Stock Is the Better Value Option?
Mon, 01 Oct 2018
20:01:00 +0000
Neurocrine Biosciences to Present New Long-Term Data Analyses on INGREZZA® (valbenazine) at the 2018 International Congress of Parkinson's Disease and Movement Disorders
SAN DIEGO, Oct. 1, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced it will present new long-term data analyses on INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), at the 2018 International Congress of Parkinson's Disease and Movement Disorders (MDS) in Hong Kong, Oct. 5-9, 2018. "Neurocrine Biosciences is committed to understanding the severity of movement disorder symptoms in patients living with tardive dyskinesia and to better understand how these symptoms manifest across body regions," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
Sun, 30 Sep 2018
19:30:00 +0000
Here's What Could Cause Neurocrine Biosciences Shares to Skyrocket
This fast-growing biotech is on track for significant earnings growth.
Fri, 28 Sep 2018
15:33:00 +0000
Healthcare: 2 Hot Biotech Stocks on Our Radar
Opportunities ahead could make it the perfect time to add these biotechs to your portfolio.
Fri, 14 Sep 2018
12:08:38 +0000
Neurocrine Biosciences: Analysts Are Mostly Positive
On September 13, Neurocrine Biosciences’ (NBIX) stock price closed at $120.88—an ~0.65% decline from its close of $121.67 the previous day. On September 13, Neurocrine Biosciences’ stock price closed at $120.88, which is ~116% growth from its 52-week low of $55.95 on September 19, 2017.
Thu, 13 Sep 2018
11:33:15 +0000
A Financial Overview of Supernus Pharmaceuticals in September
In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.
Wed, 12 Sep 2018
20:35:03 +0000
Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is the most knowledgable group I've ever been associated with (23 years). It is also the most unselfish and there is never any name calling or putting members down. ValueForum has helped me be very successful." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards